We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

RenovoRx Inc (RNXT) USD0.0001

Sell:$1.24 Buy:$1.32 Change: $0.01 (0.78%)
Market closed |  Prices as at close on 26 December 2024 | Switch to live prices |
Sell:$1.24
Buy:$1.32
Change: $0.01 (0.78%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 26 December 2024 | Switch to live prices |
Sell:$1.24
Buy:$1.32
Change: $0.01 (0.78%)
Market closed |  Prices as at close on 26 December 2024 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

RenovoRx, Inc. is a clinical-stage biopharmaceutical company. The Company is developing targeted combination therapies for high unmet medical needs with a goal of improving therapeutic outcomes for cancer patients undergoing treatment. Its Trans-Arterial Micro-Perfusion (TAMP) therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy’s toxicities versus systemic intravenous therapy. Its portfolio of cancer therapies is based on its lead product candidate, RenovoGem (gemcitabine delivered via its delivery system). Its phase III lead product candidate, RenovoGem, is a novel oncology drug-device combination product. RenovoGem is being evaluated for the treatment of locally advanced pancreatic cancer (LAPC) by the Center for Drug Evaluation and Research. Its phase III registrational trial of RenovoGem for the treatment of LAPC is called TIGeR-PaC.

Contact details

Address:
333 W Santa Clara St Ste 900
SAN JOSE
95113-1716
United States
Telephone:
+1 (408) 8002649
Website:
https://renovorx.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
RNXT
ISIN:
US75989R1077
Market cap:
$30.96 million
Shares in issue:
24.00 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Ramtin Agah
    Chairman of the Board, Co-Founder, Chief Medical Officer
  • Shaun Bagai
    Chief Executive Officer, Director
  • Ronald Kocak
    Principal Financial Officer and Accounting Officer, Vice President, Controller
  • Leesa Gentry
    Chief Clinical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.